Toward this effect, the bivalent cRGD conjugated to a methoxy-modified PIK3CB siRNA resulted in suppression of the phosphoinositide 3-kinases-protein kinase B-mammalian target of rapamycin (PI3K-AKT-mTOR)-signaling in glioblastoma, thereby inhibiting cell cycle progression and migration while enhancing tumor apoptosis in vitro and in vivo (Cen et al., 2018). Here, PIK3CB is linked to neoplasm.